42P TROP2 normalised membrane ratio (NMR) assessed by quantitative continuous scoring (QCS): Association with clinical outcomes with datopotamab deruxtecan (Dato-DXd) ± osimertinib (osi) in EGFR-mutated (EGFRm) NSCLC

Background: Dato-DXd received accelerated US FDA approval for treatment of EGFRm NSCLC based on a pooled analysis of EGFRm cohorts from TROPION-Lung05 (TL05; NCT04484142) and TROPION-Lung01 (TL01; NCT04656652).TROP2 NMR status by QCS was associated with clinical outcomes with Dato-DXd in patients (pts) with non-squamous, non-actionable genomic alteration (NSQ non-AGA) NSCLC who were treated in TL01 and TROPION-